Palvella Reports QTORIN Rapamycin Improves Disease Severity in Children in Phase 3 SELVA Study
Palvella Therapeutics will present previously reported QTORIN rapamycin trial results with new pediatric analyses at PeDRA on Oct. 15, 2026. Phase 3 SELVA pediatric analyses showed improved overall disease severity and lesion characteristics in children with microcystic lymphatic malformations. Phase 2 TOIVA pediatric